MedTrace Logo

Impact of Alpha Lipoic Acid Efficacy in Burning Mouth Syndrome

NCT05729529 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2023-02-15

No results posted yet for this study

Summary

A double-blind placebo-controlled trial is conducted in order to evaluate the efficacy of alpha lipoic acid (ALA) and determine the statistical significance of the outcome variables. Burning mouth syndrome (BMS) is defined as an oral burning sensation in the absence of clinical signs which could justify the syndrome.

Recent studies suggest the existence of neurological factors as a possible cause of the disease.

Conditions

  • Burning Mouth Syndrome

Interventions

OTHER

Lipoid acid gel

Topic lipoid acid gel used with topic oral gel used on tongue

DRUG

Placebo

Placebo oral gel used on tongue

Sponsors & Collaborators

  • University of Catania

    lead OTHER

Principal Investigators

  • Gaetano Isola · Università degli Studi di Catania

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-01-20
Primary Completion
2023-05-25
Completion
2023-05-30

Countries

  • Italy

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05729529 on ClinicalTrials.gov